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Morphine is an agonist of the m and k receptors, whose activation results in analgesia. Morphine-like agonists
act through the m opioid receptors to cause pain relief, sedation, euphoria and respiratory depression.
Morphine is glucuronidated and sulfated at positions 3 and 6; the plasma concentration ratios correlate
positively with birth weight, which probably reflects increased liver weight with increasing birth weight.
Moreover, morphine clearance correlates positively with gestational age and birth weight. Steady-state
morphine plasma concentrations are achieved after 24-48 hours of infusion, but the glucuronide metabolite
plasma concentrations do not reach steady state before 60 hours. The morphine-3-glucuronide metabolite has
lower clearance, a shorter half-life and a smaller distribution volume compared with the morphine-6
metabolite, which is the most active morphine-like agonist. Ordinary doses cause constipation, urinary retention
and respiratory depression. Neonatal pain relief may require a blood level of approximately 120 ng/ml, whereas
lower levels (20-40 ng/ml) seem adequate for children. A bibliographic search was performed using the PubMed
database and the keywords ‘‘morphine metabolism neonate’’ and ‘‘morphine pharmacokinetics neonate’’. The
initial and final cutoff points were January 1990 and September 2015, respectively. The results indicate that
morphine is extensively glucuronidated and sulfated at positions 3 and 6, and that the glucuronidation rate is
lower in younger neonates compared with older infants. Although much is known about morphine in neonates,
further research will be required to ensure that recommended therapeutic doses for analgesia in neonates are
evidence based.
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’ INTRODUCTION
Morphine is an agonist of both the m and the k receptors,
and activation of these receptors results in analgesia.
Morphine-like agonists mediate their effects via the m opioid
receptors to cause pain relief, sedation, euphoria and
respiratory depression. Morphine blocks the transmission
of nociceptive signals, activates signaling by pain-modulat-
ing neurons to the spinal cord, and inhibits transmission
from primary afferent nociceptors to dorsal horn sensory
projection cells (1). With increasing doses, the degree of
analgesia increases until an anesthetic level is reached. The
onset of morphine-induced analgesia after intravenous
administration is relatively slow (6-30 min), partly because
of its limited lipid solubility and its slow rate of penetration
through the blood-brain barrier. Additionally, morphine
undergoes significant first-pass metabolism; thus, oral doses
must be six-fold greater than parenteral doses to achieve the
same degree of analgesia (2). However, the short-term
elimination half-life of 3-4 hours in adults limits the duration
of analgesia.
Morphine, which is the main alkaloid of opium, was first
obtained from poppy heads in 1805 (3). The half-life in
preterm infants is 6-12 hours but is very variable and is
inversely related to gestational age at birth. Certain tissue
accumulation occurs with sustained use, with a distribution
volume of approximately 2 l/kg. Elimination is more rapid in
infants older than 2 months, with a half-life of approximately
1 hour in 1- to 6-year-old children. Neonatal pain relief may
require blood levels of approximately 120 ng/ml, although
overdose effects start to appear at levels exceeding 300 ng/ml.
Lower levels, or approximately 20-40 ng/ml, appear to be
adequate in older children (3). The higher levels required in
the newborn may reflect drug receptor differences and low
metabolization to morphine-6-glucuronide, which is essen-
tially the active metabolite. Tolerance may develop with
prolonged treatment, and withdrawal symptoms can also
occur. Addiction has not been observed with neonatal use for
pain relief, but there are concerns that long-term opiate
exposure may affect visual function. Moreover, neonatal
abstinence due to opiate withdrawal produces sleep/wake
abnormalities, feeding difficulties, weight loss and seizures.
An analysis of the management of morphine weaning has
recently been presented elsewhere (4).DOI: 10.6061/clinics/2016(08)11
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REVIEW
Morphine is frequently used in infants undergoing
therapeutic hypothermia. Morphine’s affinity for the m
opioid receptors is reduced in hypothermia, rendering it less
effective, at least in the early stages; however, because the
clearance of morphine is lower in the very young newborn,
accumulation may occur if higher doses are used. Accord-
ingly, the dose of morphine should be controlled and
reduced if the infant is adequately sedated after 24-48 hours,
lessening the risk of accumulation and toxicity (3). In
addition, naloxone should be readily available to reverse
marked hypotension and bradycardia. Paralytic ileus,
delayed gastric empting, urine retention and tolerance may
develop after prolonged use; therefore, weaning should be
performed slowly.
This review covers the results reported on the subject over
the past 25 years. In particular, this review puts into
perspective the most significant progress made in terms of
the metabolic pathways and the pharmacodynamic proper-
ties of morphine in human neonates and infants. The most
controversial point related to morphine use in the perinatal
period is the dosage to be employed to both ensure adequate
action and minimize safety concerns. We believe that this
review offers an adequate framework within which morphine
can be used.
’ BIBLIOGRAPHIC SEARCH
A bibliographic search was performed using the PubMed
database as the search engine. January 1990 and September
2015 were the initial and final cutoff points, respectively.
Three other specific references were also inserted for historical
clarification. When the keywords ‘‘morphine metabolism
neonate’’ and ‘‘morphine pharmacokinetics neonate’’ were
used, a total of 69 original research papers were located. The
abstracts and subsequently the full articles were analyzed,
and ultimately, a total of 24 articles were selected for analysis.
In addition, the books Neonatal Formulary (3) and NeoFax, by
Young and Mangum, were consulted (5). Methadone, other
hypnoanalgesic drugs and central stimulants will be briefly
referred to wherever appropriate, and alternative sedative
agents have been recently reviewed (6,7).
’ RESULTS
Metabolism of Morphine
Table 1 displays data relating to ten original research
reports mainly centered on the metabolism of morphine.
These reports are presented in chronological sequence as a
historical survey of the evolution of the topic.
Choonara et al. (8) studied the sulfation of morphine in
9 children and 7 preterm neonates. All of the neonates and
3 children had detectable concentrations of morphine-3-sulfate
in the urine, but none had a detectable concentrations of
morphine-6-sulfate in the urine. Additionally, none of the
children had a detectable concentration of morphine-3-sulfate
in the plasma. Oxidation and sulfation are thought to be minor
pathways of morphine metabolism, so the ratio of morphine-3-
sulfate to morphine can be used as an index of sulfation. This
ratio, however, is very low, even in the neonatal period,
indicating that the contribution of sulfation to the metabolism of
morphine is minimal. In another study, Choonara et al. (9)
demonstrated that full-term neonates and older infants have a
well-developedmechanism for the glucuronidation of morphine
at both position 3 and position 6. In all cases, the plasma
concentrations of morphine-3-glucuronide were higher than
those of morphine and the plasma concentrations of morphine-
6-glucuronide were higher than those of morphine in 7 of the
10 infants in whom morphine-6-glucuronide was detectable.
Table 1 - Metabolic parameters of morphine in neonates. The figures are means. The adult values are normal and are used for
comparison.
Reference Number
of cases
Dose Developmental
stage
Age at treatment Procedure Clearance
(ml/min/kg)
Notes
8 16 Continuous
infusion
7 Preterm
9 Term
NA Analgesia NA Morphine-3 sulfate present in
urine
Morphine-6 sulfate absent in urine
Morphine sulfation negligible in
neonates
9 12 Infusion 5 Preterm
7 Term
NA Analgesia NA M-3G present in all patients
M-6G present in 10 patients
10 16 Average dose
92±19 mg/kg
Preterm
25-32 weeks g
o5 to 66 days
(mean: 10)
Ventilation NA M-3G and M-6G found in two
thirds of acutely ill preterm
newborns
11 49 20 mg/kg/h
30 mg/kg/h
Term 1 day to 2.5 years Post-surgery 5-21 Morphine sulfate clearance equal
to adult values at age 2-25 months
12 17 100-200 mg/kg +
infusion
Preterm
(26-34 weeks)
1 day Analgesia NA M-3G detected in plasma on day 1
M-6G detected in plasma on day 1
13 10 100 mg/kg Preterm
(25-34 weeks)
1 day Analgesia NA Detected in plasma:
Morphine
Morphine-3-glucuronide at 2 hours
Morphine-6-glucuronide at 24 hours
14 35 Dose adjusted to
reach steady
state: 20 ng/ml,
7-25 mg/kg/h
Term 1-7 days
8-90 days
91-180 days
180-380 days
Before and
after cardiac
surgery
9.2-48.9
before surgery
5.5-21.7
after surgery
M-3G detected from day 1 2 hours
after dosing
M-6G detected from day 2
15 31 Dose adjusted
through effect
Preterm Term 10 days Ventilation Increase from
0.8-6.5
To provide a rational basis for
morphine administration
16 68 10 mg/kg/h Term o7 days (52)
47 days (16)
Major
surgery
NA To determine age-related
differences in morphine needs
M-3G: Morphine-3-glucuronide; M-6G: Morphine-6-glucuronide.
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The ratio of morphine-3-glucuronide to morphine in the plasma
was described as a useful index of glucuronidation in the
presence of normal renal function. Bhat et al. (10) examined the
manner in which morphine is metabolized in 16 acutely ill very
premature (25-32 weeks gestational age) infants. Morphine was
detected in the plasma at 4 hours after dosing in 13 patients and
at 24 hours in 12 patients, and large amounts of unmetabolized
morphine were found in the urine at 4 and 24 hours. Nearly two
thirds of acutely ill preterm infants born at less than 32 weeks
gestational age exhibited metabolism of morphine to morphine-
3-glucuronide, which is not an analgesic and to morphine-6-
glucuronide, which is a highly potent analgesic and sedative.
McRorie et al. (11) investigated the clearance of morphine and
morphine sulfate in 49 children aged 1 day to 2.5 years with
normal renal and hepatic function and stable hemodynamics.
Morphine clearance reached the adult value between the second
week and the sixth month of life. The formation clearance of
morphine glucuronides was correlated with age, whereas the
formation clearance of morphine sulfate was independent of
age. In another study, Hartley et al. (12) studied morphine
pharmacokinetics in 17 premature neonates (26-34 weeks of
gestation) after intravenous infusion during the first 24 hours of
life. Infants received either a standard loading dose of morphine
(100 mg/kg/h) or a high dose (200 mg/kg/h), both followed by
a maintenance infusion. The mean plasma concentrations of
morphine after 2 and 24 hours were respectively 99±12.9 and
96.4±3.2 for the standard-dose regimen and 184±37.7 and
319±71.2 for the high-dose regimen. Morphine-3-glucuronide
plasma concentrations achieved approximately 20% and 80% of
morphine values at 2 and 24 hours, respectively. Morphine-6-
glucuronide could not be detected at 2 hours but attained
20-25% of the morphine plasma concentration by 24 hours.
Furthermore, Hartley et al. (13) provided the first clear-cut in
vivo indication of the differential development of uridine
diphosphate glucuronosyltransferase in neonates. In premature
neonates (25-34 weeks of gestation), only morphine and
morphine-3-glucuronide were detected in plasma obtained over
the first 24 hours of life; morphine-6-glucuronide could only be
quantified after 24 hours. The concentrations of both active
metabolites increased significantly with increasing birth weight.
However, the ratio of the morphine-6 concentration to the
morphine-3-glucuronide concentration decreased with increas-
ing birth weight (and gestational age). High plasma concentra-
tions of morphine appeared to be well tolerated. Lynn et al. (14)
analyzed morphine clearance values in 35 infants (age 1-380
days) who received the drug by continuous intravenous
infusion for analgesia before and after surgery. The leading
dose and infusion rates (adjusted to age) were calculated to
reach a steady-state concentration of 20 ng/ml and measured
morphine concentrations (ng/ml) were effectively 20 ng/ml for
age 1-7 days, but 10 ng/ml for all other ages. Morphine
clearance increased steadily with age before cardiac surgery but
was consistently lower (5.5-21.7 ml/min/kg) after surgery. The
ratio of the morphine-6-glucuronide concentration to the
morphine concentration ranged from 1.9-2.1. Infants under-
going non-cardiac surgery cleared morphine more efficiently
than infants of equivalent age undergoing cardiac surgery. In
addition, the clearance of morphine matured more quickly in
infants undergoing non-cardiac surgery (by 1-3 months of age)
than in those receiving morphine after cardiac surgery (by 6-12
months of age). Saarenmaa et al. (15) provided a rational basis
for morphine administration in preterm infants in the immedi-
ate postnatal period by determining the clearance and evaluat-
ing the efficacy and adverse effects of continuous infusions.
A steady-state morphine concentration was achieved between
24 and 48 hours of infusion, but morphine-6- and morphine-3-
glucuronide concentrations did not reach steady state until
60 hours. Morphine clearance correlated significantly with gesta-
tional age and birth weight, and total morphine clearance and
the serum concentration ratios of the metabolites to morphine
correlated with gestational age and birth weight. However, the
steady-state serum morphine concentration did not significantly
correlate with the pain score value during the second day of life.
Thus, the evaluation of pain control must be the prime guide
for morphine dosing. Bouwmeester et al. (16) investigated the
age-related differences in morphine requirements and metabo-
lism in full-term neonates following major surgery. Continuous
morphine infusion (10 mg/kg/h) and intermittent morphine
(30 mg/kg per 3 hours) were equally effective. Younger neonates
(7 days or less) had significantly higher morphine plasma
concentrations and a lower ratio of morphine-6-glucuronide to
morphine. Mechanically ventilated neonates (424 hours) also
had significantly higher morphine plasma concentrations. The
control of pain by analgesics other than morphine has been
recently reviewed elsewhere (17-19).
Pharmacokinetics of Morphine
The 14 articles discussing the pharmacokinetics of mor-
phine and its metabolites are summarized in Table 2. For the
purposes of this discussion, they have been ordered as a
function of the specific procedures on which they focused.
When no procedure was specified in the report, morphine
was considered to have been used as an analgesic.
Analgesia
Hartley et al. (20) studied morphine pharmacokinetics in
17 premature neonates (gestational age 26-34 weeks) during
the first day of life. Infants received either a standard or a
high dose (Table 2). The kinetic parameters obtained after
administration of the standard dose are also summarized in
Table 2. Morphine and morphine-3-glucuronide were
detected at 2 and 24 hours, whereas morphine-6-glucuronide
was only detected in the 24-hour samples. The morphine-3-
glucuronide plasma concentration achieved approximately
20% and 80% of the morphine values at 2 and 24 hours,
respectively, whereas morphine-6-glucuronide attained 20-
25% of the morphine plasma concentration by 24 hours.
High plasma concentrations of morphine appeared to be well
tolerated. Although the mean arterial blood pressure
decreased during the first six hours of treatment, this finding
was not statistically significant. Two infants experienced
transient muscle rigidity, but no evidence of seizures was
noted. There appeared to be no clinical advantage in using
the high-dose regimen. Bhat et al. (21) studied morphine
pharmacokinetics after a single dose of 100 mg/kg was
administered to 20 newborn infants who were born at 26-40
weeks of gestation and who were less than 5 days of age
when treated. Kinetic parameters are displayed in Table 2.
Ten infants had an average gestational age and birth weight
of 28 weeks and 1,020 g, respectively; seven had a gestational
age and a birth weight of 33 weeks and 1,870 g, respectively;
and three had a gestational age and a birth weight of
40 weeks and 3,000 g, respectively. The morphine clearance
rate increased as a function of gestational age at a rate of
0.9 ml/min/kg per week of gestation. Between 18% and 22%
of the drug was protein bound in the plasma. The authors
concluded that there is marked variation in morphine
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pharmacokinetics during the neonatal period and that nearly
80% of the intravenously infused drug remains free, which
might explain the high sensitivity to morphine in this age
group, especially during the first week of life. Finally, Scott
et al. (22) determined morphine pharmacokinetics in 48
premature neonates varying in post-conceptional age and
evaluated the behavioral pain response in relationship to
serum morphine concentrations. Kinetic parameters are
displayed in Table 2. Morphine clearance in premature
neonates increased with post-conceptional age, but no
differences were observed in distribution volume among
the various groups in terms of post-gestational age. Again,
the behavioral pain response did not correlate with clearance
or distribution levels.
Mechanical Ventilation
Anand et al. (23) performed a multicenter study on 898
ventilated (maximum 14 days) preterm neonates (22-30
weeks gestational age) from 16 centers who were randomly
assigned to placebo (n=449) or morphine (n=449). Kinetic
parameters are displayed in Table 2. Clearance increased
from 2.05 l/h/70 kg at 22 weeks to 6.04 l/h/70 kg at 30
weeks gestational age. The distribution volume in preterm
neonates was 190 l/70 kg and did not change with age.
Barret et al. (24) studied the pharmacokinetics of morphine,
morphine-6-glucuronide and morphine-3-glucuronide in 19
ventilated preterm and term newborn infants. Kinetic
parameters are displayed in Table 2. The patients received
diamorphine loading followed by infusion over 14-149
hours. Morphine was detected in the plasma of all subjects.
The clearance of morphine, but not its distribution volume,
correlated with age. The morphine-3-glucuronide and
morphine-6-glucuronide formation clearances were 2.5±1.8
and 0.46±0.32 ml/min/kg, respectively. Moreover, their
respective excretion clearances were 0.46±0.60 and 0.71±0.36
ml/min/kg, their respective half-lives were 11.1±11.3 and
Table 2 - Demographic and pharmacokinetic parameters of morphine in neonates. The figures are means. The adult values (34) are
normal and are used for comparison.
Reference Number of
cases
Dose Developmental stage Age at
treatment
Procedure Half-life
(hours)
Clearance
(ml/min/kg)
or (l/h/70 kg)
Distribution
volume
(l/kg)
20 17 100-200 mg/kg +
infusion
Preterm (26-34 weeks) Day 1 Analgesia 8.75 2.4 ml/min/kg 1.82
21 20 100 mg/kg Preterm (10-28 weeks)
Preterm (7-33 weeks)
Term (3)
o5 days Analgesia 10.0
7.4
6.7
3.4 ml/min/kg
9.6 ml/min/kg
15.5 ml/min/kg
1.84
5.18
2.9
22 48 50 mg/kg + infusion Preterm (24-27 weeks)
Preterm (28-31 weeks)
Preterm (32-35 weeks)
Preterm (36-39 weeks)
NA Pain response
control
6.6 2.3 ml/min/kg
3.2 ml/min/kg
4.5 ml/min/kg
7.8 ml/min/kg
2.2
2.4
2.6
3.2
23 898 100 mg/kg +
infusion versus
placebo
Preterm (22-38 weeks) 5 days to
54 weeks
Ventilation +
Analgesia
NA Increased
from 2.0 l/h/70
kg to
6.0 l/h/70 kg
2.7
24 19 50 mg/kg
diamorphine +
infusion
Preterm (24-39 weeks)
Term
1-37 days Ventilation 11.1
(M3G)
18.2 (M6G)
4.6 ml/min/
kg
0.55 (M3G)
1.03 (M6G)
25 27 100 mg/kg Term 1 week to
6 months
Ventilation
(n=4) or
surgery (n=23)
8.1 to 2.6 8.7-28.0 ml/
min/kg
NA
26 19 10-100 mg/kg +
infusion
Preterm (12)
Term (7)
NA Ventilation for
respiratory
distress
9.6 2.6 ml/min/kg 2.05
27 10 20-100 mg/kg/h Preterm
Term
1-70 days Ventilation 6.8 (1-7
days)
3.9 (older)
6.3 (1-7 days)
23.8 (older)
2.9
28 14 100 mg/kg +
infusion
Term o7 days
Lasting
14 days
Membrane
oxygenation
NA 2.2 l/h/70 kg,
increased to
10.5 l/h/70 kg
2.0,
increasing
to 5.0
29 11 infusion Term NA Membrane
oxygenation
NA 11.7 ml/min/
kg
NA
30 7 NA Term 1 day to
12 months,
lasting 40-
103 hours
Membrane
oxygenation
NA 9.1 during
increase
17.6 post-
oxygenation
NA
31 184 100 mg/kg +
infusion
Term 0-3 years Surgery NA 71 l/h/70 kg 1.94
32 26 50 mg/kg + infusion
diamorphine
Preterm
(26-38 weeks)
NA Surgery 8.9±3.3 3.6 ml/min/kg 2.7
33 13 100-200 mg/kg +
infusion
Preterm (8)
Term (5)
NA Surgery 9.3
3.7
2.8 ml/min/kg
4.7 ml/min/kg
2.4
1.7
34 20 50 mg/kg +
infusion
Term NA Surgery 6.6 2.1 ml/min/kg 5.0
35 Standard
values
---- ---- Adults -------- 1.9 35 ml/min/kg 3.3
M-3G: Morphine-3-glucuronide; M-6G: Morphine-6-glucuronide; NA: Not available.
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18.2±13.6 hours, and their respective distribution volumes
were 0.55±1.13 and 1.03±0.88 l/kg. Thus, the metabolism
of morphine in neonates was similar to that in adults, in
terms of the respective contributions of each glucuronide
pathway. In another study, Pokela et al. (25) reported on
the pharmacokinetics of morphine in 27 term infants aged
1 week to 6 months who received a single intravenous
dose of 100 mg/kg morphine after surgery (n=23) or during
mechanical ventilation (n=4). Kinetic parameters are dis-
played in Table 2. The half-life decreased with age, with the
highest value in 10 neonates younger than 1 week, a
moderate value in 10 infants aged 1 week, and the lowest
value in 7 infants aged from 2-6 months. The clearance of
morphine increased correspondingly with age but was
significantly lower in critically ill infants and it approached
adult values after the age of 1 month. Chay et al. (26)
evaluated morphine pharmacokinetics and pharmacody-
namics after continuous intravenous infusion of morphine
in 19 neonates, included preterm (n=12) and term (n=7)
neonates, whose lungs were ventilated to relieve respiratory
distress. The pharmacokinetic parameters are summarized in
Table 2. In neonates experiencing adverse effects of mor-
phine, the plasma clearance was found to be decreased by
50%. The morphine concentration required to produce
adequate sedation was 125 ng/ml in 50% of patients,
whereas concentrations above 300 ng/ml were potentially
associated with adverse effects. Morphine-6-glucuronide was
not detected in the plasma of any neonate, which may
explain why neonates require high plasma concentrations of
unchanged morphine for sedation. Additionally, the half-life,
clearance and distribution volumes were not significantly
different between preterm and term.
Extracorporeal Membrane Oxygenation
Lynn and Slattery (27) studied the pharmacokinetics of
morphine in 10 mechanically ventilated infants (gestational
age 36-41 weeks) aged 1 day to 10 weeks when treated.
Pharmacokinetic parameters are displayed in Table 2. Rates
of infusion ranged from 20-100 mg/kg/h, and the duration of
infusion varied from 14 hours to 15 days. Infants aged 1-4
days showed longer elimination half-lives than older infants
did (6.8 versus 3.9 hours), and clearance in newborns was less
than one third of that found in older infants (6.3 versus 23.8
ml/min/kg). The combination of lower clearance and a
longer elimination half-life in newborns may well explain the
prolonged duration of action for morphine in very young
infants. Peters et al. (28) studied the pharmacokinetics of
morphine in 14 neonates undergoing veno-arterial extra-
corporeal membrane oxygenation (ECMO). Procedures
started at age o7 days and were extended for 14 days.
Pharmacokinetic parameters are displayed in Table 2. Clear-
ance at the start of ECMO was low but increased rapidly and
reached normal levels after 14 days. The only covariates
affecting clearance were size and age. The distribution
volume increased throughout ECMO, to a volume 2.5 times
greater than that in postoperative children. This finding
suggests that serum concentrations decrease during the first
10 days and that dose adjustments should be performed.
Clinicians should also be aware that serum morphine
concentrations may decrease over time in children receiving
morphine infusion while undergoing ECMO; this is attribu-
table to increased clearance and distribution volume. Conse-
quently, morphine therapy should be guided by clinical
monitoring, preferably using validated comfort scales.
Geiduschek el al. (29) determined whether the serum
morphine concentration changes during the first 3 hours of
ECMO and whether morphine absorption onto the mem-
brane oxygenator is responsible for these changes. However,
morphine concentrations were no different from baseline to
3 hours after beginning ECMO and no significant difference
in the morphine concentration was observed in samples
taken immediately proximal compared with distal to the
membrane oxygenator throughout ECMO. The initiation of
ECMO thus does not lead to a significant decrease in the
serum morphine concentration and there is no uptake of
morphine into the membrane oxygenator of the ECMO
circuit. Morphine clearance for infants receiving ECMO is
variable. Dagan et al. (30) studied the effect of ECMO on the
pharmacokinetics of morphine in 7 infants aged 1 day to
12 months who required ECMO lasting for 40-103 hours. The
reported pharmacokinetic parameters are displayed in
Table 2. Morphine clearance rates doubled and serum
concentrations were halved after ECMO was discontinued;
consequently, higher doses of morphine were required to
maintain adequate sedation. The acute decrease in the serum
concentrations of morphine after cessation of ECMO were
probably caused by the enhanced clearance of the drug.
Surgery
Bouwmeester et al. (31) described the pharmacokinetics
and metabolism of morphine and its metabolites in 184
children aged 3-6 years. Population parameter estimates for a
one-compartment, first-order elimination model were stan-
dardized to a 70 kg body weight and are displayed in
Table 2. The clearance of the morphine metabolites increased
with age in parallel with glomerular filtration rate matura-
tion. Thus, (i) morphine-3-glucuronide is the predominant
metabolite of morphine in young children and (ii) the total
body morphine clearance reaches 80% of adult values
by 6 months. In another investigation, Barrett et al. (32)
studied the pharmacokinetics of morphine in 26 premature
newborns (26-38 weeks gestational age) who received a
loading dose of 50 mg/kg, followed by an intravenous
infusion of 15 mg/kg/h of diamorphine. The pharmacokinetic
parameters are summarized in Table 2. The mean steady-state
morphine plasma concentration for a diamorphine infusion
rate of 15 mg/h was 62.5±22.8 ng/ml. There was a direct
relationship between the gestational age of the patients and
the clearance and half-life of morphine, but no relationship
was found between gestational age and distribution volume.
These results suggest that the currently used dosing regimen
for diamorphine achieves a safe effective morphine concentra-
tion in the premature newborn but that the loading dose could
be modified to achieve a more rapid onset of analgesia.
Mikkelsen et al. (33) investigated the pharmacokinetics of a
single dose of 15 mg/kg morphine in 5 term infants and
8 preterm infants before and after surgery. Twelve of the
infants received mechanical ventilation. The median half-life
in the preterm group was 9.2 hours, compared with 3.7 hours
in the term infants. No significant difference was found
between term and preterm in terms of distribution volume or
plasma clearance. The terminal half-life decreased progres-
sively with increasing gestational age. No correlation was
found between clearance and gestational age. Finally, a larger
inter-individual variation in morphine plasma concentration
was observed in term infants.
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Safety and Efficacy
Farrington et al. (34) evaluated the efficacy and safety of
morphine sulfate in 20 neonates requiring and recovering
from surgery. Pharmacokinetic parameters are displayed in
Table 2. Following surgery, each subject received an intrave-
nous morphine loading dose (50 mg/kg), followed by
continuous infusion (15 mg/kg/h) for a minimum of
24 hours. The mean percentage of unchanged morphine
recovered in the urine was 39±19% of the dose administered
over 12 hours. Continuous morphine therapy appears to be
effective in controlling neonatal postoperative pain, as
suggested by subjective observations and decreased serum
b-endorphin content.
Thumel et al. (35) reported normal morphine pharmaco-
kinetic values for healthy adults, displayed for comparison in
Table 2.
’ DISCUSSION
In vivo observations of morphine, paracetamol (acetami-
nophen), and propofol disposition throughout childhood
confirm the overall low glucuronidation activity in neonates
observed in in vitro studies. Compared with data related to
phase 1 isoenzyme activity, data on the isoenzyme-specific
phenotypic activity of uridine diphosphate glucuronosyl-
transferase and its covariates in neonates are limited. The
present review endeavored to summarize the state of the art
concerning this facet of neonatology. Stimulation of the
central nervous system has been the focus of other recent
reviews (36,37).
As observed in Table 1, nine of the selected articles
reported on metabolic aspects of morphine processing in
neonates (8-16). The most important information to be
gathered from these papers is as follows: (a) sulfation is a
minor component of morphine transformation (8,11); (b)
glucuronidation is an essential metabolic step, converting
morphine either to morphine-3-glucuronide or to morphine-
6-glucuronide (9,10,12-14); (c) the relatively inactive mor-
phine-3-glucuronide is produced as early as day 1 of life in
preterm and term neonates, whereas the highly active
morphine-6-glucuronide only appears on day 2 (12,13); and
(d) there is no obvious correlation of dose with analgesic/
sedative effects during the first days of life, especially in
preterm neonates.
Table 2 summarizes the pharmacokinetics of morphine, as
reported in the 15 articles selected for this review (20-34). The
most significant features of these reports are as follows: (a)
the half-life is long in the earliest stages of life but rapidly
decreases as the metabolic pathways develop (21,27,33); (b)
conversely, but reflecting the same underlying characteristic,
morphine clearance increases rapidly in parallel with the
decrease in half-life (21-23,25,27,28,30,33); and (c) no clear
tendency emergeds from these studies regarding distribution
volume, which appears to be independent of age.
Other relevant aspects may be stressed here:
A. Neonates who were mechanically ventilated for longer
than 24 hours had significantly higher morphine plasma
concentrations than spontaneously breathing neonates did 12
and 24 hours after surgery (10,15,23-27).
B. As noted above, in premature infants who were given
morphine intravenously, only morphine-3-glucuronide was
detected in the plasma 2 hours after dosing, whereas
morphine-6-glucuronide was detected in the plasma 24 hours
after dosing. The plasma concentration ratios of morphine-
3-glucuronide to morphine and morphine-6-glucuronide
to morphine increased significantly with increasing birth
weight (9). Morphine-6-glucuronide is a potent opioid agonist,
whereas morphine-3-glucuronide functionally antagonizes
several of the effects of both morphine and morphine-
6-glucuronide (9). Considering these opposing properties,
the proportions of the two metabolites formed are clearly
relevant.
C. The pharmacokinetics of morphine vary considerably in
neonates. This characteristic probably reflects immaturity of
hepatic glucuronidation and altered hepatic blood flow
during periods of acute illness and shunting of blood away
from the liver by the ductus venosus.
D. Between 18% and 22% of morphine is bound to plasma
protein in neonates (22), whereas in adults, the percentage
bound to plasma protein is 35±2% (34). The greater the
proportion of morphine that remains free is, the greater the
proportion of morphine that could enter the neonate’s brain
is, which might explain the increased sensitivity to morphine
for any given dosage in neonates.
E. Estimates in adults indicate that more than 70% of
morphine undergoes glucuronide conjugation and that 5-10%
undergoes sulfate conjugation. In total, 3-10% of unconjugated
morphine is excreted in the urine. Large variation in clearance
during the first few days of life could be a reflection of
immature conjugation systems or of factors related to poor
hepatic blood flow.
The main limitation of the present review is the fact that
only one source of information was consulted, even though a
few references were manually inserted, mainly referring to
the author’s contribution to this field of knowledge.
In conclusion, morphine is extensively glucuronidated at
positions 3 and 6 and is also sulfated at these positions. The
rate of glucuronidation of morphine is lower in younger
neonates compared with older infants, and the half-life and
the clearance of morphine are lower in preterm infants than
in term infants. Although much is already known about
morphine in neonates, further research will be required to
ensure that the therapeutic doses recommended for analgesia
in neonates are evidence based.
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